SLN
Silence Therapeutics Plc
$7.16
-$0.15(-2.05%)
59
Overall
--
Value
66
Tech
52
Quality
Market Cap
$342.11M
Volume
93.93K
52W Range
$1.97 - $18.29
Target Price
$30.50
Order:
Income Statement
| Metric | Trend | Chart | 2014 Dec | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $15.0K | -- | $770.0K | $16.0K | -- | $244.0K | $5.5M | $12.4M | $17.3M | $25.4M | ||
| Total Revenue | $15.0K | -- | $770.0K | $16.0K | -- | $244.0K | $5.5M | $12.4M | $17.5M | $25.4M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $8.9M | $7.1M | -- | -- | -- | -- | $3.8M | $7.5M | $10.9M | $10.3M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $-8.9M | $-7.1M | -- | -- | -- | $244.0K | $1.7M | $5.0M | $6.6M | $15.1M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $3.3M | $9.8M | $12.7M | $14.4M | $20.6M | $23.0M | $34.2M | $50.8M | $55.2M | $64.7M | ||
| Research & Development | -- | $7.1M | $8.7M | $7.9M | $9.7M | $13.3M | $20.2M | $30.8M | $35.6M | $44.0M | ||
| Research Expense | -- | -- | -- | -- | -- | -- | -- | -- | $35.6M | $44.0M | ||
| Selling, General & Administrative | $3.3M | $2.7M | $4.0M | $6.5M | $10.8M | $9.6M | $14.0M | $20.0M | $19.6M | $20.6M | ||
| General & Administrative Expenses | $3.3M | $2.7M | $4.0M | $6.5M | $10.8M | $9.6M | $14.0M | $20.0M | $19.6M | $20.6M | ||
| Salaries & Wages | -- | -- | -- | -- | -- | -- | -- | -- | -- | $13.1M | ||
| Depreciation & Amortization | -- | -- | -- | -- | -- | -- | -- | $-66.0K | -- | $498.0K | ||
| Depreciation & Amortization | -- | -- | -- | -- | -- | -- | -- | $-66.0K | -- | $498.0K | ||
| Amortization | -- | -- | -- | -- | -- | -- | -- | $-2.0K | -- | $36.0K | ||
| Other Operating Expenses | -- | -- | -- | -- | -- | -- | $3.4M | -- | -- | $1.3M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-12.1M | $-9.8M | $-11.9M | $-14.4M | $-20.6M | $-22.7M | $-32.5M | $-45.8M | $-48.6M | $-49.6M | ||
| EBITDA | $-12.0M | $-9.4M | $-10.4M | $-3.8M | $-20.5M | $-22.4M | $-35.5M | -- | $-46.8M | $-47.7M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $15.0K | -- | $33.0K | $16.0K | $8.0K | $47.0K | $2.2M | ||
| Intinc | $139.0K | $175.0K | $161.0K | -- | $39.0K | $27.0K | $129.0K | $10.0K | $226.0K | $1.4M | ||
| Net Non-Operating Interest Income/Expense | $-147.0K | $-340.0K | $-1.5M | $15.0K | $-39.0K | $6.0K | $-113.0K | $-2.0K | $179.0K | $-706.0K | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | $-3.7M | $-44.0K | -- | -- | ||
| Other Income/Expense | -- | -- | -- | -- | -- | -- | $-3.7M | $-44.0K | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-12.0M | $-9.4M | $-10.4M | $-3.8M | $-20.5M | $-22.8M | $-36.0M | $-45.9M | $-47.3M | $-48.2M | ||
| Pre-Tax Income | $-12.0M | $-9.4M | $-10.4M | $-3.8M | $-20.5M | $-22.9M | $-36.0M | $-45.9M | $-47.4M | $-50.3M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $-892.0K | $-2.8M | $-1.9M | $-2.2M | $-2.1M | $-3.3M | $-3.5M | $-6.4M | $-6.9M | $-7.0M | ||
| NET INCOME | ||||||||||||
| Net Income | $-11.1M | $-6.6M | $-8.4M | $-1.6M | $-18.4M | $-19.6M | $-32.5M | $-39.4M | $-40.5M | $-43.3M | ||
| Net Income (Continuing Operations) | $-11.1M | $-6.6M | $-8.4M | $-1.6M | $-18.4M | $-19.6M | $-32.5M | $-39.4M | $-40.5M | $-43.3M | ||
| Net Income (Discontinued Operations) | $-11.1M | $-6.6M | $-8.4M | $-1.6M | $-18.4M | $-19.6M | $-32.5M | $-39.4M | $-40.5M | $-43.3M | ||
| Net Income (Common Stockholders) | $-11.1M | $-6.6M | $-8.4M | $-1.6M | $-18.4M | $-19.6M | $-32.5M | $-39.4M | $-40.5M | $-43.3M | ||
| Normalized Income | $-12.9M | $-12.2M | $-12.3M | $-5.9M | $-22.6M | $-26.2M | $-39.5M | $-52.3M | $-54.2M | $-57.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-12.1M | $-9.8M | $-12.7M | $-14.4M | $-20.6M | $-23.0M | $-38.0M | $-58.2M | $66.1M | $75.0M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $50.4M | $64.0M | $69.8M | $69.9M | $70.3M | $75.1M | $81.8M | -- | $96.6M | $111.3M | ||
| Average Shares Outstanding (Diluted) | $50.4M | $64.0M | $69.8M | $69.9M | $70.3M | $75.1M | $81.8M | -- | $96.6M | $111.3M | ||
| Shares Outstanding | $36.7M | $36.7M | $36.7M | $36.7M | $36.7M | $36.7M | $36.7M | $36.7M | $36.7M | $36.7M | ||
| Basic EPS | $-0.22 | $-0.10 | $-0.12 | $-0.02 | $-0.26 | $-0.26 | $-0.40 | -- | $-0.42 | $-0.39 | ||
| Basic EPS (Continuing Operations) | $-0.22 | $-0.10 | $-0.12 | $-0.02 | $-0.26 | $-0.26 | $-0.40 | -- | $-0.42 | $-0.39 | ||
| Diluted EPS | $-0.22 | $-0.10 | $-0.12 | $-0.02 | $-0.26 | $-0.26 | $-0.40 | -- | $-0.42 | $-0.39 | ||
| Diluted EPS (Continuing Operations) | $-0.22 | $-0.10 | $-0.12 | $-0.02 | $-0.26 | $-0.26 | $-0.40 | -- | $-0.42 | $-0.39 | ||
| OTHER METRICS | ||||||||||||
| Loss And Loss Adjustment Expected Incurred | -- | -- | -- | -- | -- | -- | -- | -- | -- | $2.1M | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | -- | -- | $10.9M | $10.3M | ||
| Other Gand A | $3.3M | $2.7M | $4.0M | $6.5M | $10.8M | $9.6M | $14.0M | $20.0M | $19.6M | $20.6M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SLN | $7.16 | -2.1% | 93.93K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Silence Therapeutics Plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW